Clinical-stage developer of small-molecule senolytics that selectively clear pathologic senescent cells driving age-related disease.
San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →